Dolutegravir And Rilpivirine

Introduction Overview

Generic Name

dolutegravir and rilpivirine

Brand Name

Juluca

Dosage Form

Oral tablets

Drug Class

Antiviral combinations

Pharmacokinetics

Absorption:
Dolutegravir and rilpivirine, the two active agents in Juluca, are rapidly absorbed from the gastrointestinal tract after oral administration. The bioavailability of dolutegravir is approximately 70%, increasing when taken with food, which also enhances rilpivirine absorption significantly. Rilpivirine exhibits optimal absorption with a moderate to high-fat meal; hence, Juluca tablets must always be taken with a meal to ensure adequate systemic exposure. The time to peak concentration (Tmax) is approximately 2 to 4 hours for both drugs.

Distribution:
Dolutegravir is highly bound (>98.9%) to plasma proteins, predominantly albumin and alpha-1-acid glycoprotein, facilitating extensive tissue distribution. Rilpivirine also exhibits high plasma protein binding (>99.7%), which limits free active drug concentration but prolongs half-life. Both drugs exhibit good penetration into lymphoid tissues, essential for targeting HIV reservoirs. However, rilpivirine poorly penetrates the central nervous system (CNS), limiting CNS-related effects.

Metabolism:
Dolutegravir undergoes metabolism primarily via liver uridine diphosphate glucuronosyltransferase (UGT1A1), with minor involvement of cytochrome P450 isoenzyme CYP3A4. This metabolic pathway reduces inter-individual variability and drug interaction potential. Rilpivirine is extensively metabolized by CYP3A4. These metabolic pathways make the drugs susceptible to inducers or inhibitors of these enzymes, impacting plasma concentrations.

Elimination:
Dolutegravir is eliminated mostly via hepatic metabolism, with a terminal half-life of approximately 14 hours, allowing once-daily dosing. Less than 1% is eliminated unchanged in urine. Rilpivirine displays a longer terminal half-life of approximately 50 hours, permitting dosing once daily. It is primarily excreted via feces as metabolites and unchanged drug. Renal clearance is minimal. Both drugs’ elimination profiles promote sustained plasma concentrations that enable convenient once-daily single-tablet regimens.

Clinical Implications:
The pharmacokinetic profiles of dolutegravir and rilpivirine underscore the necessity of administering Juluca with food to maximize absorption. The metabolic interactions particularly with CYP3A4 modulators require careful consideration to avoid under- or overdosing. Adjustments of concomitant medications and monitoring for efficacy and toxicity are essential, especially in patients with hepatic impairment or on concurrent strong CYP inducers or inhibitors.

Dosage Forms

Available Dosage Forms:
Juluca is available as combination oral tablets containing a fixed-dose of dolutegravir 50 mg and rilpivirine 25 mg per tablet. The tablets are film-coated and intended for once-daily oral administration.

Dosages for Adults and Adolescents:
The standard adult and adolescent dosing regimen for Juluca is one tablet orally once daily with a meal. This single-tablet regimen is approved for patients with HIV-1 infection who are virologically suppressed (HIV-1 RNA <50 copies/mL) for at least 6 months on a stable antiretroviral regimen without history of treatment failure or resistance-associated substitutions to either component.

Specific Patient Populations:
- No dosage adjustment is recommended for mild to moderate hepatic impairment; caution is advised in severe hepatic impairment due to lack of clinical data.
- No dosage adjustments are necessary for mild to moderate renal impairment; not recommended in patients with severe renal impairment (eGFR <30 mL/min) or end-stage renal disease as rilpivirine and dolutegravir elimination may be affected.
- Use in pediatric populations under 12 years or weighing less than 35 kg is not established.
- Not recommended during pregnancy unless the potential benefit outweighs the risks; a negative pregnancy test prior to initiation is recommended.

Clinical Guidelines:
Patients must take Juluca with food to enhance absorption and maintain therapeutic drug levels. The once-daily single-tablet fixed-dose combination simplifies adherence compared to multi-pill regimens. Usage is restricted to patients previously suppressed on stable antiretroviral therapies for at least 6 months to mitigate the risk of resistance development. Monitoring for viral load and potential resistance mutations is essential post-initiation.

Mechanism Of Action

Juluca combines two distinct antiretroviral agents – dolutegravir and rilpivirine – that target HIV-1 replication through complementary mechanisms to achieve synergistic viral suppression.

Dolutegravir is an integrase strand transfer inhibitor (INSTI). It specifically binds to the active site of the HIV-1 integrase enzyme, preventing the strand transfer step crucial for the integration of viral DNA into the host genome. By inhibiting this process, dolutegravir effectively blocks the replication cycle of HIV at the stage of proviral DNA formation, which is essential for the production of new infectious virions. Its high binding affinity and slow dissociation from integrase provide a sustained antiviral effect.

Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). It binds non-competitively to the HIV-1 reverse transcriptase enzyme at an allosteric site distinct from the nucleoside triphosphate binding site. This binding induces a conformational change that inhibits the enzyme's activity, thus preventing the conversion of viral RNA to DNA, an early and critical step in viral replication. Rilpivirine’s enhanced potency and improved resistance profile relative to earlier NNRTIs contribute to its effectiveness.

The combination therapy capitalizes on targeting two key enzymatic steps in the HIV replication cycle – reverse transcription and integration – reducing viral replication and limiting the emergence of resistant strains. Clinical studies demonstrate that Juluca maintains viral suppression effectively and is generally well-tolerated with a favorable safety profile.

Comparative Mechanisms and Evidence:
Compared to other regimen classes such as protease inhibitors, Juluca's agents have fewer metabolic drug interactions and generally better lipid profiles. Clinical trials have validated the efficacy of Juluca in maintaining virologic suppression in patients stable on other antiretroviral therapies, offering a simplified regimen that supports adherence and quality of life. Research supports the mechanistic rationale that dual inhibition at key enzymatic steps synergistically enhances antiviral efficacy while minimizing drug resistance.

Pharmacological Actions

Inhibits HIV-1 integrase enzyme via dolutegravir component, preventing viral DNA integration into the host genome.
Blocks reverse transcriptase activity via rilpivirine component, halting the reverse transcription of viral RNA to DNA.
Suppresses HIV-1 replication by dual blockade of distinct viral enzymatic pathways.
Exhibits potent antiretroviral activity against wild-type and certain resistant HIV-1 strains.
Provides sustained viral suppression with once-daily dosing convenience.
Demonstrates high plasma protein binding, prolonging pharmacological activity.
Facilitates immune system preservation by reducing HIV viral load.
Exhibits minimal impact on cytochrome P450 enzyme system via dolutegravir, reducing drug interactions.
Rilpivirine component contributes to a favorable resistance profile among NNRTIs.
Synergistic pharmacologic effect from combining integrase and reverse transcriptase inhibitors.
Reduces the formation of new infectious HIV virions.
Improves patient adherence due to single-tablet fixed-dose formulation.
Decreases HIV-associated morbidity by effective suppression of the viral lifecycle.
Limits emergence of resistance mutations through combination antiviral therapy.
Supports maintenance therapy in virologically suppressed HIV-1 infected individuals.

Therapeutic Or Clinical Uses

Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
Maintenance therapy for HIV-1 patients virologically suppressed on a stable antiretroviral regimen for at least 6 months.
Simplified once-daily antiretroviral regimen to enhance adherence.
Replacement regimen for stable HIV-1 patients to reduce pill burden.
Part of combination antiretroviral therapy to prevent HIV progression to AIDS.
Treatment option with favorable safety and drug interaction profile.
Used to maintain viral suppression in patients without known resistance to individual components.
Alternative regimen for patients intolerant to nucleoside reverse transcriptase inhibitors (NRTIs).
Treatment regimen keyed to reduce long-term toxicity associated with multi-drug therapies.
Recommended to minimize the emergence of resistance mutations in stable patients.
Utilized in patients requiring regimen switch due to adverse effects or other considerations.
Supports improved quality of life through reduced dosing frequency and pill count.
May be used in patients with mild to moderate hepatic impairment with caution.
Approved for adults and adolescents weighing at least 35 kg.
Integral part of safe and effective antiretroviral treatment programs.

Side Or Adverse Effects

Headache.
Nausea.
Diarrhea.
Depression, including mood changes, feelings of low self-worth, and loss of interest in activities.
Anxiety and sadness.
Suicidal thoughts or behaviors.
Signs of allergic reaction: hives, swelling of face, lips, tongue, or throat, difficulty breathing.
Serious skin reactions or drug hypersensitivity.
Liver dysfunction symptoms: nausea, vomiting, loss of appetite, right upper abdominal pain, dark urine, clay-colored stools, jaundice.
Immune reconstitution inflammatory syndrome (IRIS), presenting as exacerbation of opportunistic infections.
Swelling in neck or throat (enlarged thyroid).
Neurological symptoms: trouble speaking or swallowing, problems with balance or eye movement, weakness, or prickly sensations.
Menstrual changes in females and impotence in males.
Fatigue and generalized weakness.
Rare but serious psychiatric effects including suicidal ideation requiring close monitoring.

Precautions

Use effective contraception and avoid pregnancy during treatment, especially in first trimester due to potential fetal risk.
Monitor liver function tests periodically due to risk of hepatic adverse effects.
Use cautiously in patients with a history of mental health disorders, including depression and suicidal ideation.
Avoid use in patients with known hypersensitivity to dolutegravir or rilpivirine.
Ensure viral suppression has been maintained for at least 6 months prior to initiating Juluca.
Patients should avoid abrupt discontinuation to reduce risk of viral rebound and resistance.
Monitor for signs of immune reconstitution inflammatory syndrome after treatment initiation.
Cautiously use in patients with moderate hepatic impairment; insufficient data in severe impairment.
Regularly assess renal function, although dose adjustment is generally not necessary for mild/moderate impairment.
Taken with food exclusively; do not substitute with meal replacement drinks to ensure proper absorption.
Avoid co-administration with strong enzyme inducers or acid-reducing agents unless proper timing adjustments are made.
Advise patients not to share medication to prevent misuse and resistance development.
Educate patients about potential neuropsychiatric side effects and to report mood changes promptly.
Regular viral load monitoring to detect virologic failure or resistance emergence.
Avoid breastfeeding as HIV can be transmitted through breast milk.

Warnings

Potential for birth defects if taken during the first trimester of pregnancy; effective contraception mandatory.
Contraindicated in patients with hypersensitivity to dolutegravir or rilpivirine.
Risk of serious, life-threatening hypersensitivity reactions including Stevens-Johnson syndrome.
Drug interactions that may reduce Juluca efficacy could lead to treatment failure and resistance.
May cause neuropsychiatric adverse events including depression, anxiety, and suicidal ideation.
Not recommended for patients with history of HIV treatment failure or with known viral resistance to components.
Patients must be closely monitored for signs of hepatic toxicity and elevated liver enzymes.
Immune reconstitution inflammatory syndrome can occur after initiating therapy.
Not suitable for initiation in patients with high viral loads or low CD4 counts without prior suppression.
Avoid concomitant use with dofetilide as it may cause severe or fatal cardiac toxicity.
Inappropriate co-administration with certain anticonvulsants and tuberculosis medications due to significant interactions.
Avoid use in breastfeeding women as HIV transmission via breast milk is possible.
Missed doses may diminish viral suppression and increase resistance risk; adherence is critical.
Store tablets properly in original container away from moisture and heat for stability.
Do not substitute with other meals or skip meals when administering tablets to avoid subtherapeutic levels.

Contraindication

Known hypersensitivity to dolutegravir or rilpivirine or any component of the formulation.
Concurrent use with dofetilide due to risk of serious or fatal cardiac arrhythmias.
Patients with previous virologic failure on rilpivirine or dolutegravir-containing regimens.
Co-administration with strong CYP3A4 inducers such as carbamazepine, phenobarbital, phenytoin, rifampin, rifapentine, and St. John's wort.
Concurrent use with more than one dose of systemic dexamethasone.
Use in pregnancy during the first trimester without strict medical indication and monitoring.
Patients with severe hepatic impairment where safety has not been established.
Breastfeeding due to risk of HIV transmission to infant.
Concomitant use with proton pump inhibitors like esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole due to reduced rilpivirine absorption.
Co-administration with drugs that significantly alter gastric pH affecting rilpivirine absorption without adequate dosing interval.
Use alongside antacids or supplements containing calcium, magnesium, or aluminum without appropriate timing separation.
In patients unable to take tablets with food as rilpivirine absorption depends on food intake.
Avoid in individuals with known resistance-associated mutations to dolutegravir or rilpivirine.
Use contraindicated with buffered medications that interfere with absorption.
Co-administration with certain histamine-2 receptor antagonists (famotidine, cimetidine, nizatidine, ranitidine) without appropriate dosing separation.

Drug Interactions

Dofetilide: co-administration contraindicated due to risk of severe or fatal cardiac arrhythmias.
St. John's wort: induces CYP3A4 leading to decreased exposure of rilpivirine and dolutegravir, risking loss of virologic response.
Systemic dexamethasone (multiple doses): strong CYP3A4 inducer reducing therapeutic levels of Juluca.
Carbamazepine, oxcarbazepine, phenobarbital, phenytoin: potent CYP3A4 inducers that significantly reduce Juluca plasma concentrations.
Rifampin and rifapentine: strong inducers of CYP3A4 enzyme significantly lowering antiretroviral drug levels.
Proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole): reduce absorption of rilpivirine leading to sub-therapeutic antiviral effect.
Antacids and laxatives containing calcium, magnesium, aluminum: bind dolutegravir and rilpivirine reducing absorption; maintain dosing separation of at least 4 hours before or 6 hours after Juluca.
Vitamin or mineral supplements containing calcium or iron: may reduce absorption if not taken appropriately with food and timing.
Histamine-2 receptor antagonists (famotidine, cimetidine, nizatidine, ranitidine): decrease rilpivirine plasma concentrations; recommend dosing Juluca at least 4 hours before or 12 hours after these agents.
Buffered medications: may interfere with Juluca absorption leading to reduced efficacy.
Other CYP3A4 inducers and inhibitors can alter dolutegravir and rilpivirine levels, necessitating therapy adjustment or avoidance.
Concomitant use of multiple antiretrovirals with overlapping toxicities requires careful clinical assessment.
Herbal supplements and over-the-counter medicines should be disclosed to healthcare providers to prevent interactions.
Medications altering gastric pH or motility can impact rilpivirine and dolutegravir absorption.
No significant interactions have been observed with certain standard concomitant medications, but patient monitoring remains essential.

Preparations Of The Drug

Juluca fixed-dose combination tablets containing 50 mg dolutegravir and 25 mg rilpivirine.
Film-coated, oval-shaped oral tablets designed for once-daily administration.
Packaged with moisture-absorbing packets in original bottles to ensure stability.
Supplied in containers with varying tablet quantities for prescription use.
Available only by prescription for oral use with meal intake.
Each tablet combines fixed doses to simplify treatment and improve adherence.
Storage recommendations include room temperature away from excessive moisture and heat.
Accompanied by medication guides highlighting administration instructions and warnings.
Manufactured under strict quality control to ensure uniform dosing and bioavailability.
Commercially available as brand name Juluca, with no generics currently marketed.
Formulation optimized for pharmacokinetic synergy between dolutegravir and rilpivirine.
Uniform the appearance and taste optimized for patient compliance.
Packaged with patient information leaflets outlining side effects and contraindications.
Standardized batch release specifications for purity, potency, and dissolution profiles.
Compatible with most concomitant oral medications when prescribed with caution.